Dengue Vaccine Globally
- A vaccine to prevent dengue (Dengvaxia®) is licensed and available in some countries for people ages 9-45 years old. The World Health Organization recommends that the vaccine only be given to persons with confirmed prior dengue virus infection.
- The vaccine manufacturer, Sanofi Pasteur, announced in 2017 that people who receive the vaccine and have not been previously infected with a dengue virus may be at risk of developing severe dengue if they get dengue after being vaccinated.
Dengue Vaccine in the United States
- In May 2019, Dengvaxia® was approvedexternal icon by the U.S. Food and Drug Administration (FDA) in the United States for use in children 9-16 years old living in an area with endemic dengue (the US territories of American Samoa, Guam, Puerto Rico and the US Virgin Islands), with laboratory confirmed prior dengue virus infection.
- Information on the vaccine’s availability in the US territories is pending.
- The US Advisory Committee on Immunization Practices (ACIP) has not yet made recommendations on Dengvaxia.
- The ACIP comprises medical and public health experts who develop recommendations on the use of vaccines in the civilian population of the United States. The recommendations stand as public health guidance for safe use of vaccines and related biological products.
Administration of Dengvaxia
- Three doses of vaccine are required. Each shot is spaced 6 months apart.
Page last reviewed: May 3, 2019